NAMS (NewAmsterdam Pharma Co NV) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NewAmsterdam Pharma Co NV's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

NewAmsterdam Pharma Co NV's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

NewAmsterdam Pharma Co NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV LT-Debt-to-Total-Asset Chart

NewAmsterdam Pharma Co NV Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

NewAmsterdam Pharma Co NV Quarterly Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial								-	-	-	-	-

NewAmsterdam Pharma Co NV LT-Debt-to-Total-Asset Calculation

NewAmsterdam Pharma Co NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.202	/	864.62
	=	0.00

NewAmsterdam Pharma Co NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.202	/	864.62
	=	0.00

NewAmsterdam Pharma Co NV (NAS:NAMS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NewAmsterdam Pharma Co NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

KH6:Germany

Address

Gooimeer 2-35, Naarden, NH, NLD, 1411 DC

Website

https://www.newamsterdampharma.com

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.